Medulloblastoma: “Onset of the molecular era”

Pavan Kumar Dhanyamraju, Trupti N. Patel, Sinisa Dovat

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Among brain tumors, Medulloblastoma (MB) is one of the most common, malignant, pediatric tumors of the cerebellum. It accounts for ~20% of all childhood central nervous system (CNS) tumors. Despite, tremendous advances in drug development processes, as well as novel drugs for MB the morbidity and mortality rates, remain high. Craniospinal radiation, high-dose chemotherapy, and surgical resection are the primary therapeutic strategies. Tremendous progress in the field of “genomics” with vast amounts of data has led to the identification of four distinct molecular subgroups in medulloblastoma: WNT group, SHH group, group-III, and group-IV. The identification of these subgroups has led to individualized treatment strategies for each subgroup. Here, we discuss the various molecular subgroups of medulloblastoma as well as the differences between them. We also highlight the latest treatment strategies available for medulloblastoma.

Original languageEnglish (US)
Pages (from-to)9931-9937
Number of pages7
JournalMolecular Biology Reports
Issue number12
StatePublished - Dec 2020

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics


Dive into the research topics of 'Medulloblastoma: “Onset of the molecular era”'. Together they form a unique fingerprint.

Cite this